KOSDAQBiotech & Pharma052020

Stcube

₩5,940▼ 2.14%2026-11-18 close
Market Cap
₩403.8B
Turnover
₩700M
Volume
120K
Shares out.
68M
PER
—
PBR
8.4×
EPS
-₩421
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue rebounds, losses widen; trial data is the swing factor

Stcube's revenue has risen for two straight quarters in 2026, but its operating loss widened to KRW 9.75 billion in the third quarter, and the business outlook rests heavily on nelmastobart's clinical trials and licensing talks.

  1. 1

    Stcube posted operating losses and net losses attributable to controlling shareholders in each year from 2022 through 2025, with a KRW 23.5 billion operating loss and operating cash flow of -KRW 19.8 billion in 2025.

  2. 2

    Quarterly revenue bottomed at KRW 1.36 billion in the first quarter of 2026, then rose to KRW 1.5 billion and KRW 2.2 billion in the next two quarters, while the third-quarter operating loss widened to KRW 9.75 billion.

  3. 3

    Interim phase 2 data for nelmastobart in non-small cell lung cancer, announced by the company on October 27, 2026 (preliminary), showed an objective response rate of 25.7% and a disease control rate of 88.6% among 35 evaluable patients. These are interim company figures, separate from audited results.

  4. 4

    Most revenue comes from the cosmetics business, so top-line movements depend largely on that segment, while discussion of enterprise value leans more on the clinical pipeline and potential licensing deals.

  5. 5

    The four quarters from the fourth quarter of 2025 through the third quarter of 2026 add up to KRW 28.6 billion in net losses attributable to controlling shareholders, so a price-to-earnings ratio cannot be calculated; whether a licensing deal is signed is the key variable for interpreting the share price.

02

Business structure

Stcube, founded in 1989 and listed on KOSDAQ in 2001, runs a cosmetics business, a biopharmaceutical business focused on drug discovery, and a distribution business for industrial lens modules.

Cosmetics account for most of its revenue, at 87% of revenue in the first nine months of 2025 by one data provider, and at 95.71% in another company-profile tally. Its in-house skincare products are sold through Olive Young and Lotte Duty Free and exported to Japan and Taiwan.

The biopharmaceutical segment contributes little revenue so far. The core pipeline is nelmastobart, an antibody that targets BTN1A1, which the company describes as a novel immune checkpoint protein distinct from PD-1 and PD-L1.

Two clinical programs are running: a phase 1b/2 trial in metastatic colorectal cancer, which completed enrollment of 61 patients in January 2026, and a phase 2 trial in non-small cell lung cancer, which began dosing its first patient in January 2026.

The competitive landscape includes existing PD-1 and PD-L1 checkpoint inhibitors and targeted cancer drugs, and the company is aiming at patients who do not respond adequately to these treatments. In 2017 the company licensed its PD-L1 antibody STT-001 for Greater China to Taiwan's ALPS Biotech.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.5B-₩5.8B−387.7%
2025Q4₩2.7B-₩7B−254.9%
2026Q1₩1.4B-₩7.3B−536.1%
2026Q2₩1.5B-₩6.1B−403.3%
2026Q3₩2.2B-₩9.8B−443.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩6.3B-₩18.9B-₩18.9B−300.1%−36.9%19.2%
2023₩5.8B-₩26B-₩24.5B−446.9%−69.4%30.2%
2024₩11.3B-₩22.6B-₩21.4B−200.2%−22.7%18.7%
2025₩7B-₩23.5B-₩21.8B−336.1%−30.2%25.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a reported annual basis, revenue fell from KRW 6.3 billion in 2022 to KRW 5.83 billion in 2023, a 7.5% decline, then rose to KRW 11.3 billion in 2024, a 93.9% increase, which is the largest year in the 2022 to 2025 window.

Revenue then dropped to KRW 6.98 billion in 2025, a 38.2% decline, and 2023 is the smallest year. Operating losses were KRW 18.9 billion in 2022, KRW 26 billion in 2023, KRW 22.6 billion in 2024 and KRW 23.5 billion in 2025, and the company recorded losses in all four years.

The operating margin was -300.1% in 2022, -446.9% in 2023, -200.2% in 2024 and -336.1% in 2025. The smallest margin loss came in 2024, the year of highest revenue, so revenue scale and loss size did not move in the same direction.

Net losses attributable to controlling shareholders were KRW 18.9 billion, KRW 24.5 billion, KRW 21.4 billion and KRW 21.8 billion for 2022 through 2025, and the net loss including non-controlling interests is reported at the same amounts.

Operating cash outflow was -KRW 16.1 billion in 2022, -KRW 24.7 billion in 2023, -KRW 23.9 billion in 2024 and -KRW 19.8 billion in 2025, so the outflow narrowed in 2025. At the end of 2025, total equity was KRW 72.1 billion, total liabilities were KRW 18.1 billion, and the debt ratio was 25.1%.

Quarterly revenue went from KRW 1.5 billion in the third quarter of 2025 to KRW 2.74 billion in the fourth quarter, an 82.0% jump, then fell to KRW 1.36 billion in the first quarter of 2026, a 50.2% drop.

It then rose to KRW 1.5 billion in the second quarter and KRW 2.2 billion in the third quarter, up 46.4% from the prior quarter and 46.2% from a year earlier.

Over the same stretch, operating losses were KRW 5.83 billion, KRW 6.98 billion, KRW 7.31 billion, KRW 6.06 billion and KRW 9.75 billion, so the loss widened again in the third quarter of 2026 even as revenue grew, which means cost pressure outpaced the revenue gain.

In the third quarter of 2025, a sharp drop in industrial lens module sales was cited as a cause of weaker results (BusinessPost). R&D expenses for 2025 were KRW 11.15 billion on a consolidated basis (Wisereport).

05

Industry analysis

Stcube is a clinical-stage drug developer whose revenue base is cosmetics, with pharmaceutical sales still small. The patients it targets are in areas where existing treatments show limited response.

According to press reports, MSS (microsatellite stable) colorectal cancer accounts for about 95% of colorectal cancer patients, yet these patients barely respond to existing immunotherapies (The Bio News).

In non-small cell lung cancer, the target group is patients whose disease has progressed after first-line treatment. Single-agent docetaxel, widely used in Korea, is reported to deliver progression-free survival of about three months and overall survival of about six months (Money Today).

Against that backdrop, the 25.7% objective response rate is an interim figure released by the company. The evaluable group is only 35 patients and the median follow-up is four months, which limits its use as a firm benchmark.

In the same release, the company said the response was comparable to combining the PD-L1 inhibitor atezolizumab with osimertinib, a characterization that reflects the company's own interpretation.

Across the biopharma sector, clinical data from antibody pipelines and licensing agreements serve as the common yardstick for valuation. On that yardstick, Stcube has been accumulating clinical data, but it has not yet disclosed a signed licensing deal.

06

Outlook

In its October 27, 2026 release, the company said 45 of 62 target patients (73%) had enrolled in the non-small cell lung cancer phase 2 trial, and that progression-free survival by blinded independent central review, the primary endpoint, will be assessed in sequence as enrollment and follow-up continue.

In the same release, no interstitial lung disease-related adverse events were reported among 13 EGFR-mutated patients, while myalgia was the most common treatment-related adverse event, affecting 18 of 45 treated patients (40.0%).

In the colorectal trial, interim results released on June 2, 2026 (data cutoff April 28, 2026) showed among 58 evaluable patients 5 partial responses, 45 stable disease and 8 progressive disease, and median overall survival had not yet been reached.

The company said it is reviewing combinations of nelmastobart with EGFR-targeted therapy.

A spatial analysis of 17 samples found differences in immune cell makeup even within BTN1A1-positive tumors, and the company plans further analysis to validate patient selection using BTN1A1 expression and the tumor microenvironment.

On licensing, the company said in its September and October 2026 releases that talks are ongoing and that its data is shaping the structure of those discussions, but no signed deal or terms have been disclosed.

Pipeline expansion reportedly includes a basket trial in other solid tumors and parallel development of a BTN1A1-based bispecific antibody.

07

Valuation

PER
—
PBR
8.4×
ROE
-44.5%
EPS
-₩421
BPS
₩735
Dividend per share
₩0

Because net losses attributable to controlling shareholders have continued over the last four quarters, a price-to-earnings ratio cannot be calculated. With earnings unable to explain the share price, a large part of the market value appears to rest on clinical results and the prospect of licensing deals.

The price-to-book ratio is in a high range, meaning market value is well above book equity. Total equity at the end of 2025 was KRW 72.1 billion against total liabilities of KRW 18.1 billion, but operating cash outflow has been negative every year, which remains a financial burden.

Dividend yield is effectively negligible, so an approach based on dividends does not hold. Valuation discussion for this stock therefore depends on whether operating losses narrow, how the nelmastobart trial data develops, and the terms of any licensing agreement.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Novel target and early clinical signals

The company describes BTN1A1 as a novel immune checkpoint protein it first identified. In the interim phase 2 lung cancer data, 35 evaluable patients showed an objective response rate of 25.7% and a disease control rate of 88.6%.

No interstitial lung disease-related adverse events were reported among 13 EGFR-mutated patients. These are preliminary interim figures released by the company.

Licensing talks ongoing

In its September and October 2026 releases, the company said licensing discussions for nelmastobart are underway and that its lung cancer data is shaping their structure and depth. The company has a prior licensing history, having licensed its PD-L1 antibody for Greater China in 2017. No signed deal has been disclosed so far, and terms and timing have not been made public.

Quarterly revenue recovery

Third-quarter 2026 revenue was up 46.2% from a year earlier. The debt ratio at the end of 2025 was 25.1%, which is a comparatively low level of liabilities relative to equity.

09

Bear factors

Four years of losses and cash outflow

Operating losses continued for four straight years from 2022 through 2025, and operating cash flow was negative in every one of those years.

The operating loss widened to KRW 9.75 billion in the third quarter of 2026, and net losses attributable to controlling shareholders totaled KRW 28.6 billion over the last four quarters. Revenue recovery has not yet translated into narrower losses.

Limited trial sample size and follow-up

The lung cancer interim results rest on 35 evaluable patients and a median follow-up of four months. In the colorectal trial, 5 of 58 evaluable patients had a partial response and 8 had progressive disease.

Median overall survival has not been reached, but the small sample and short follow-up limit how firmly the data can be read.

Revenue concentration and valuation burden

Most revenue comes from cosmetics, so results from the pharmaceutical pipeline are some distance from reported revenue. With net losses over the last four quarters, a price-to-earnings ratio cannot be calculated, and the price-to-book ratio is in a high range. With no licensing deal disclosed, the market value may be highly sensitive to clinical developments.

10

Risk factors

Clinical and regulatory risk

Nelmastobart's lung cancer data consists of interim response measures, and the primary endpoint of progression-free survival is still being assessed in sequence. If the program fails to advance to later stages, a significant portion of the pipeline's value could be reassessed. Myalgia was reported in 40.0% of treated patients.

Funding risk

Operating losses were KRW 23.5 billion in 2025, and operating cash outflow was -KRW 19.8 billion, with large annual burn continuing. Total equity at the end of 2025 was KRW 72.1 billion, and net losses over the last four quarters total KRW 28.6 billion.

If licensing deals are delayed and additional funding is needed, dilution for existing shareholders could increase.

Business mix and ownership structure risk

Revenue depends on cosmetics and industrial lens distribution, and performance in these two businesses drives the overall profit and loss. According to press coverage, the ownership chain runs from CEO Jung Hyun-jin through S-Science and STCube & Company to Stcube.

Given this layered structure, the consolidation scope and related-party transactions should be reviewed in the periodic reports.

11

What to watch next

  1. Date not set (upon company disclosure)

    Results for the primary endpoint of progression-free survival in the lung cancer phase 2 trial. Whether the interim response rate carries through to confirmed survival data is the next checkpoint.

  2. Date not set (upon company disclosure)

    Whether a nelmastobart licensing agreement is signed and its terms. The upfront payment and scope of rights would change how the funding position and pipeline value are read.

  3. Around mid-February 2027

    Preliminary fourth-quarter and full-year 2026 results. The 2025 preliminary results were disclosed on February 20, 2026 (Daily Invest). The annual revenue and operating loss trend will be compared against the audited 2025 figures.

  4. Late March 2027

    Submission of the 2026 annual report, the next periodic filing. The 2026 operating margin, debt ratio and cash flow are the next items to check.

12

Overall view

Stcube is building a BTN1A1-based antibody pipeline on top of a business whose revenue is mostly cosmetics.

Reported results show operating losses and net losses attributable to controlling shareholders in each year from 2022 through 2025, and in the third quarter of 2026 the operating loss widened to KRW 9.75 billion even though revenue rose for two consecutive quarters.

The 25.7% objective response rate in the nelmastobart lung cancer phase 2 interim is a preliminary figure from the company and should be read alongside 35 evaluable patients and a four-month median follow-up.

Strengths include a novel target, accumulating clinical data and ongoing licensing talks, while weaknesses include long-running losses, cash outflow, no disclosed licensing deal and a high price-to-book ratio.

The next checkpoints are the progression-free survival results, whether a licensing agreement is signed, the preliminary 2026 fourth-quarter results and the 2026 annual report, and the reading of the business will depend on how these play out.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. mt.co.kr
  2. newspim.com
  3. pharmnews.com
  4. view.asiae.co.kr
  5. stcube.com
  6. jiwonfund.kr
  7. grandpharm.com
  8. prnewswire.com
  9. dailyinvest.kr
  10. comp.wisereport.co.kr
  11. file.alphasquare.co.kr
  12. moneypie.net
  13. etoday.co.kr
  14. businesspost.co.kr
  15. thebionews.net
  16. etoday.co.kr
  17. sedaily.com
  18. jobkorea.co.kr

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis